Stocktoria
AXIM BIOTECHNOLOGIES, INC. AXIM
OTC · stock · Pharmaceutical Preparations · website · IPO 2013-04-09
AXIM BIOTECHNOLOGIES, INC. statistics & valuation
Market cap$1.0M
P / S25.8×
Net margin-20395.0%
FCF margin-2607.7%
Net debt$4.9M
Enterprise value USD$5.9M
Earnings yield EBIT/EV-46.6%
Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2023 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 95.6% | 9.9% | -227.5% | -2.5% | — | — |
| Operating margin | -6961.0% | -9607.1% | -52425.6% | -23114.5% | -2574.5% | -6619.5% | -7988.8% | -20451.3% | — | — |
| Net margin | -20395.0% | -37348.0% | -70343.1% | -26517.2% | -3453.0% | -8761.7% | -12346.0% | -20539.2% | — | -189.8% |
| FCF margin | -2607.7% | — | -23132.8% | -4180.1% | — | — | -2750.0% | -3098.1% | — | — |
| Return on assets | -195.5% | -68.3% | -148.2% | -301.2% | -323.3% | -190.1% | -400.9% | -800.0% | -78.9% | -3336.2% |
| Return on equity | 105.3% | 44.8% | 129.4% | 685.7% | 111.1% | 66.3% | 245.0% | 595.4% | 100.4% | 321.8% |
| Debt / equity | -0.64× | — | — | — | — | — | — | — | — | — |
| Current ratio | 0.03 | 0.01 | 0.03 | 0.25 | 0.61 | 0.27 | 0.46 | 0.46 | 0.56 | 0.09 |
Computed from company filings · US · as of 2023-12-31. Facts plus Stocktoria's own computed scores — not investment advice.